Mexichem Specialty Compounds, Inc.

Waltham, MA ManufacturingNAICS 325900

Self-funded health planPlan year 2025Renews January
2,391Participants-7% vs. prior year
$5.7MEst. pharmacy spend / yrParticipants × national avg.
Jan 2027Next renewalPlan year begins January 1
#10 of 48Manufacturing in MABy participants

Overview

Mexichem Specialty Compounds, Inc. sponsors a self-funded health plan that covered 2,391 participants in plan year 2025, down 8% from the prior year. The plan year starts in January. Alongside medical, its benefits filing reports life insurance, dental, vision, short-term disability, and more.

Plan type
ERISA welfare benefit plan, self-funded (benefits paid from employer assets or a trust)
Participants
2,391 · prior year 2,586
Plan year
Begins January 1 · next renewal January 2027
Health plans filed
The Orbia US Employee Benefit Plan, plan 501 (2,391 participants)
Broker compensation
$371K across insured contracts
MedicalLife insuranceDentalVisionShort-term disabilityPrepaid legalLong-term disabilityDeath benefitsOther welfare benefits

Insurance carriers

Insured coverage reported on Schedule A. Self-funded medical claims aren't reported there.

CarrierCoverageCoveredPremiumBroker comp
Prudential Insurance Company of AmericaLife, Long-term disability2,400$2.3M$207K
Unum Insurance CompanyAccident, Critical Illness, Hospital Indemnity630$427K$97K
Blue Cross Blue Shield of Massachusetts, Inc.Vision4,239$197K$13K
Provident Life and Accident Insurance CompanyShort-term disability36$103K$21K
Arag Insurance CompanyLegal Services658$70K$7K
National Union Fire Insurance Company of Pittsburgh, PABusiness Travel Accident2,400$2K$498

Pharmacy benefit estimate

StreamRX estimate for a plan this size. Not based on this plan's claims.

$5.7M/ year

Estimated prescription spend: 2,391 participants × $2,371 national average per member. Usually higher once dependents are counted.

$147K–$363K/ year

Typical savings opportunity found in independent reviews of plans this size.

Brands with a generic available$43K–$108K
Lower-cost therapeutic alternatives$63K–$132K
Generic pricing vs. actual cost$27K–$82K
PBM contract terms$14K–$43K
The DOL's PBM fee disclosure rule first applies to this plan for the plan year beginning January 2028: semiannual PBM compensation reports and an annual audit right.

Form 5500 filing details

Filing
Form 5500 with Schedule A, plan year 2025
Plan sponsor
Mexichem Specialty Compounds, Inc.
Sponsor EIN
56-1803538
Plan number
501
Filed with
U.S. Department of Labor (EBSA) via EFAST2

Verify this filing: search EIN 56-1803538 in the Department of Labor's EFAST2 Form 5500 search.

About this data

Source: Mexichem Specialty Compounds, Inc.'s Form 5500 filing for plan year 2025 and its Schedule A insurance reports, published by the U.S. Department of Labor. "Self-funded" means the filing reports benefits paid from employer assets or a trust, with no medical insurance contract or with a stop-loss contract. Pharmacy figures are StreamRX estimates based on national averages. StreamRX is not affiliated with Mexichem Specialty Compounds, Inc..

Request a correction · Methodology